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Introduction
In recent years the use of
host–guest systems to efficient-
ly deliver drugs to cancer cells
has attracted much interest.[1]
In such systems the physico-
chemical properties of the
host–guest complex are gener-
ally superior to those of the
guest alone leading to im-
provements in efficacy and bio-
compatibility.[2] It is not sur-
prising that cisplatin,[3] the
most widely used metal-based
drug in the treatment of cancer, has been encapsulated in
various hosts to reduce the severe side-effects associated
with this drug.[4] Indeed, platinum-based drugs have been at-
tached to various structures including carbon nanotubes,[5]
proteins,[6] macrocycles[7] and dendrimers.[8] These large sys-
tems tend to accumulate preferentially in tumours due to
enhanced permeability and retention (the EPR effect) of
macromolecules in cancerous tissue.[9]
The synthesis of discrete metalla-cages is now a well-es-
tablished field in chemistry. Initially dominated by square-
planar metal centres,[10] almost all transition metals have
now been used in the preparation of metalla-cages.[11] The
field is now entering a new era in which applications as sen-
sors, micro-reactors or transporters are leading to new per-
spectives for metalla-cages.[12] These applications exploit the
ability of metalla-cages to encapsulate and release guest
molecules. This dynamic process involves different mecha-
nisms depending on the nature of the metalla-cages, namely
by partial rupture of the cage or by passage through an
aperture.[13] These two reversible guest-exchange mecha-
nisms are illustrated in Figure 1.
Recently we combined the medicinal properties of arene–
ruthenium complexes, a promising class of organometallic
drugs,[14] with aspects of supramolecular chemistry[15] to gen-
erate a new hybrid drug-delivery system, [Ru6(p-
iPrC6H4Me)6 ACHTUNGTRENNUNG(tpt)2ACHTUNGTRENNUNG(dobq)3]
6
+
(tpt=2,4,6-tripyridin-4-yl)-
1,3,5-triazine; dobq=2,5-dioxido-1,4-benzoquinonato), in
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Figure 1. Guest-exchange mechanisms involving host rupture (top) or passage through an aperture (bottom).
1
which guest molecules were encapsulated into the cavity of
the host. This host was found to encapsulate planar aromatic
compounds[16] as well as planar platinum and palladium ace-
tylacetonate (acac) complexes.[17] The biological activity of
these compounds was evaluated on human ovarian cancer
cell lines and the empty cage [Ru6(p-iPrC6H4Me)6ACHTUNGTRENNUNG(tpt)2-
ACHTUNGTRENNUNG(dobq)3]
6+ was found to have an IC50 value of 23 mm with
the carceplexes being at least an order of magnitude more
cytotoxic (the guests were not cytotoxic on their own).[17]
The ability of this host to deliver guest molecules to cells
was further confirmed by the encapsulation of a fluorescent-
labelled pyrene-R derivative, 1-(4,6-dichloro-1,3,5-triazin-2-
yl)pyrene.[18] Fluorescence experiments used to monitor the
uptake of pyrene-R into cancer cells demonstrated an
uptake of the carceplex [pyrene-RRu6(p-iPrC6H4Me)6-
ACHTUNGTRENNUNG(tpt)2 ACHTUNGTRENNUNG(dobq)3]
6+ one order of magnitude greater than that of
pyrene-R alone.[18] These systems suggest that after internal-
isation, the cage is destroyed in the cytoplasm and the re-
lease of the encapsulated molecule increases the cytotoxici-
ty, thus giving rise to an additive effect.
In an extension to this work we have prepared a series of
larger cationic hexanuclear metalla-prisms, [Ru6(p-
iPrC6H4Me)6 ACHTUNGTRENNUNG(tpt)2ACHTUNGTRENNUNG(donq)3]
6+ ([1]6+), [Ru6(p-iPrC6H4Me)6-
ACHTUNGTRENNUNG(tpt)2 ACHTUNGTRENNUNG(doaq)3]
6+ ([2]6+) and [Ru6(p-iPrC6H4Me)6ACHTUNGTRENNUNG(tpt)2-
ACHTUNGTRENNUNG(dotq)3]
6+ ([3]6+) (donq=5,8-dioxido-1,4-naphthoquinonato;
doaq=5,8-dioxido-1,4-anthraquinonato, dotq=6,11-dioxido-
5,12-naphthacenedionato) with similar sized cavities but dif-
ferent sized portals (Figure 2). Two guest molecules, Pd-
ACHTUNGTRENNUNG(acac)2 and pyrene-R, were encapsulated into the cavities of
these metalla-prisms and, in contrast to our previous work,
no rupture of the host was necessary to release the guest.
The stability constants of the host–guest systems involving
pyrene-R were studied in solution by NMR and fluores-
cence spectroscopy and the anti-proliferative activities of
the empty cages and of the host–guest systems [Pd-
ACHTUNGTRENNUNG(acac)21–3]6+ and [pyrene-R1–3]6+ were evaluated on
human ovarian cancer cell lines. The uptake and release of
pyrene-R by the [pyrene-R1–3]6+ systems were deter-
mined and correlated to the portal size of the host molecule.
Results and Discussion
The syntheses of the empty arene–ruthenium metalla-prisms
[1]6+ , [2]6+ and [3]6+ have been already described.[19,20] The
cavities of [1–3]6+ are of an equivalent size, but the use of
different OO\OO connectors controls their portal size, thus
modulating the dynamics of the host–guest systems. The en-
capsulation of Pd ACHTUNGTRENNUNG(acac)2 and pyrene-R in these cages re-
quires the addition of silver triflate to the corresponding di-
nuclear arene–ruthenium complexes [Ru2(p-iPrC6H4Me)2-
ACHTUNGTRENNUNG(OO\OO)Cl2] (OO\OO=donq, doaq and dotq) in the
presence of the trigonal tpt panels and the guest molecule,
leading to the connection of these different building blocks
around the guest to afford [Pd ACHTUNGTRENNUNG(acac)21–3]6+ and [pyrene-
R1–3]6+ (Scheme 1). All the metalla-prisms were isolated
as triflate salts and characterised by IR, UV and NMR spec-
troscopy and by elemental analysis.
The formation of [guest1–3]6+ was monitored in CD3CN
by 1H NMR spectroscopy. The resonances of the different
protons of the guest molecule and the pyridyl protons of the
tpt panels are shifted upfield upon formation of the encap-
sulated system, whereas the signals of the CH protons of the
bridging ligands (donq, doaq or dotq) are shifted downfield.
The proton resonances of the p-cymene ligands located at
the periphery of the prism are not significantly affected by
the presence of a guest molecule in the cavities of [1–3]6+ .
In the 1H NMR spectra of [Pd ACHTUNGTRENNUNG(acac)21–3]6+ , the CH and
CH3 signals of the acetylacetato ligands are shifted upfield
by around 1.7 ppm relative to the free complex, and in the
spectra of [pyrene-R1–3]6+ the signals of the CH protons
of the encapsulated aromatic
guest are all shifted upfield rel-
ative to the free molecule, the
frequencies being similar to
those observed in [pyr-
ACHTUNGTRENNUNGeneRu6(p-iPrC6H4Me)6 ACHTUNGTRENNUNG(tpt)2-
ACHTUNGTRENNUNG(dobq)3]
6+ .[16a]
The electronic absorption
spectra of [guest1–3]6+ (see
Figure 3) are characterised by
an intense high-energy band
centred at 300 nm, which may
Figure 2. Molecular structures of the metalla-prisms [1]6+–[3]6+ (colour codes: magenta=Ru, red=O,
purple=N, grey=C).
Scheme 1. Synthesis of [guest1–3]6+ .
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be assigned to a ligand-localised or intra-ligand p!p* tran-
sition. In the visible region, a series of broad low-energy
bands are observed and tentatively assigned to mixed metal-
to-ligand charge-transfer (MLCT), intra-ligand charge-trans-
fer (ILCT) and ligand p!p* transitions, with ILCT refer-
ring to intra-ligand charge transfer from the tpt panels to
the OO\OO bridging ligands.[21] In particular, in the elec-
tronic absorption spectra of [Pd ACHTUNGTRENNUNG(acac)22]6+ and [pyrene-
R2]6+ , two bands at 570 and 615 nm are remarkably well
resolved, which is consistent with the spectrum of the empty
metalla-prism [2]6+ .[20]
The infrared spectra of the metalla-prisms are dominated
by absorptions of the coordinated OO\OO bridging ligands.
It is particularly noticeable that a significant redshift of
about 20 cm1 is observed for the C=O vibration frequencies
of the quinone bridging ligands in all these spectra relative
to the frequencies of the corresponding non-coordinated
bridging ligands 5,8-dihydroxy-1,4-naphthoquinone, 5,8-di-
hydroxy-1,4-anthraquinone and 6,11-dihydroxy-5,12-naph-
thacenedione. This redshift can be attributed to a decrease
in the CO bond order upon coordination to ruthenium
atoms,[22] which is in accord with the X-ray data of the aqua-
ted metalla-clip [Ru2(p-iPrC6H4Me)2ACHTUNGTRENNUNG(donq) ACHTUNGTRENNUNG(OH2)2]
2+ .
Indeed, in this complex the lengths of the CO bonds are be-
tween 1.27(1) and 1.32(2) , which suggests an intermediate
bond order between single (~1.40 ) and double
ACHTUNGTRENNUNG(~1.20 ).[23] In addition to these C=O signals, strong ab-
sorptions due to the stretching vibrations of the triflate
anions (1260 (s), 1030 (s), 638 cm1 (m)) are observed in the
infrared spectra of all the salts [Pd ACHTUNGTRENNUNG(acac)21–3]ACHTUNGTRENNUNG[CF3SO3]6
and [pyrene-R1–3]ACHTUNGTRENNUNG[CF3SO3]6.
The host–guest properties of the [guest1–3]6+ systems
were studied in solution. We first established their stability
in water, toluene and acetonitrile at room and elevated tem-
peratures. The [Pd ACHTUNGTRENNUNG(acac)21–3]6+ systems show no signs of
cage degradation or of leaching of the guest in any of the
solvents tested, even after heating at reflux for 24 h, which
is consistent with previous observations.[19] However, all
[pyrene-R1–3]6+ systems show a rapid loss of the guest in
[D8]toluene at 80 8C but they remain intact in acetonitrile
and water. The host–guest dynamics of the two systems [Pd-
ACHTUNGTRENNUNG(acac)21–3]6+ and [pyrene-R1–3]6+ are quite different.
The most sterically demanding guest, Pd ACHTUNGTRENNUNG(acac)2, is trapped
in the cavities whereas the planar aromatic guest molecule,
pyrene-R, leaches out of the cages. These observations sug-
gest that the guest-release process involves a non-dissocia-
tive mechanism:[13] the apertures of the cages are large
enough to allow pyrene-R to pass through, whereas Pd-
ACHTUNGTRENNUNG(acac)2 is retained in the cavities of the cage compounds [1–
3]6+ . To further study the encapsulation of pyrene-R in the
metalla-prisms [1–3]6+ , diffusion-ordered NMR spectrosco-
py (DOSY) was performed.[24] As an example, the DOSY
spectra of pyrene-R, [1]6+ and pyrene-R+ [1]6+ in CD3CN
at room temperature are presented in Figure 4. These spec-
tra show that at room temperature, [1]6+ and pyrene-R+
[1]6+ possess almost identical diffusion coefficients, which
confirms the encapsulation of pyrene-R in the hydrophobic
cavity of [1]6+ . Similar results were obtained with metalla-
prisms [2]6+ and [3]6+ .
We also confirmed the stoichiometry of the host–guest
systems [pyrene-R1–3]6+ in CD3CN and (CD3)2SO by
1H NMR titrations using the molar ratio method.[25] Upon
gradual addition of pyrene-R (0.1–3.0 equiv) to a solution of
the host (4.0 mm in CD3CN and 10.0 mm in (CD3)2SO),
changes in the chemical shifts of some protons were ob-
served. The 1H NMR spectra obtained from the titration ex-
periments with [3]6+ at 21 8C in CD3CN are shown in
Figure 5. The broadening and chemical shifts of the signals
are indicative of a rapid inclusion of pyrene-R into the hy-
drophobic cavity of [3]6+ . Similar behaviour was observed in
(CD3)2SO although broadening of the pyridyl signals is
Figure 3. UV/Vis spectra of [guest1–3]6+ in CH2Cl2 (105m).
Figure 4. DOSY NMR spectra of pyrene-R (···), [1]6+ (—) and
[1]6+ +1 equivalent of pyrene-R (c) in CD3CN at 21 8C.
Figure 5. 1H NMR titrations of pyrene-R in a solution of [3] ACHTUNGTRENNUNG[CF3SO3]6 in
CD3CN at 21 8C. A) [3]
6+ (4.0 mm), B) [3]6+ +0.5 equivalents of pyrene-
R and C) [3]6+ +1.0 equivalent of pyrene-R.
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more significant and the changes in chemical shifts of the
signals corresponding to the pyrenyl protons are less pro-
nounced.
Plots of the changes in the chemical shifts (Dd) of the
signal of the Hb protons of the tpt ligands (CD3CN) or of
the signal of the Hq protons of the OO\OO ligands
((CD3)2SO) versus the molar ratio of pyrene-R to the
prisms [1–3]6+ indicate the formation of 1:1 stoichiometric
host–guest systems (see Figure 6).
The determination of 1:1 stoichiometric systems allows us
to represent the inclusion process of pyrene-R (guest) by
the metalla-cages [1–3]6+ (host) by Equation (1) in which k+
and k define, respectively, the rate constants for association
and dissociation of the [guesthost] system.
½guest þ ½host
kþ
k
! ½guest  host ð1Þ
The quotient k+/k of the rate constants for the formation
and dissociation of the host–guest system gives the thermo-
dynamic constant K and, at equilibrium, this stability con-
stant can be defined by Equation (2).
K ¼ kþ
k
¼ ½guest  host½guest½host ð2Þ
Consequently, from the plots obtained for the 1H NMR ti-
trations, thermodynamic stability constants were estimated
by using the non-linear least-squares fitting program
winEQNMR2[26] (see Table 1). The values obtained show
that at equilibrium (at constant temperature and for a given
concentration and solvent), the equilibrium is strongly shift-
ed towards the associative complexes [pyrene-R1–3]6+
rather than towards the dissociative species. The Gibbs free
energies (DG8) for the [pyrene-R1–3]6+ systems were then
determined from the corresponding stability constants ob-
tained at 21 8C in both CD3CN and (CD3)2SO from the
Gibbs free-energy equation.[25]
In contrast to the carceplex system [pyrene-RRu6(p-
iPrC6H4Me)6 ACHTUNGTRENNUNG(tpt)2ACHTUNGTRENNUNG(dobq)3]
6+ , in which the fluorescence of
the pyrene-R guest was totally quenched upon encapsula-
tion,[18] some fluorescence remains in the host–guest systems
[pyrene-R1–3]6+ (see Figure 7). Indeed, the fluorescence
of the pyrenyl part is quenched but the triazin-2-yl group
does not entirely lose its fluorescent property. The quench-
ing of the emission of the pyrenyl unit can be explained by
Figure 6. Changes in the 1H NMR chemical shifts of the signal of the Hq
protons of the OO\OO ligands versus the molar ratio of pyrene-R/ ACHTUNGTRENNUNG[1–
3]6+ in (CD3)2SO at 21 8C (top) and of the signal of the Hb protons of the
tpt ligands versus the molar ratio of pyrene-R/ ACHTUNGTRENNUNG[1–3]6+ in CD3CN at 21 8C
(bottom).
Table 1. Stability constants (K) and Gibbs free energies (DG8) for the
encapsulation of pyrene-R in [1–3]6+ determined by 1H NMR titration.
[Guesthost] system K [104 m1] DG8 [kcalmol1]
CD3CN
[a]
[pyrene-R1]6+ 4.1 6.27
[pyrene-R2]6+ 2.0 5.86
[pyrene-R3]6+ 1.2 5.56
ACHTUNGTRENNUNG(CD3)2SO
[b]
[pyrene-R1]6+ 4.4 6.32
[pyrene-R2]6+ 3.5 6.19
[pyrene-R3]6+ 2.4 5.97
[a] Titration in CD3CN at 21 8C with 4.0 mm concentration of the metal-
la-prisms. [b] Titration in (CD3)2SO at 21 8C with 10.0 mm concentration
of the metalla-prisms.
Figure 7. Fluorescence emission spectra of pyrene-R (black curve) and
[pyrene-R1–3]6+ (blue curve= [pyrene-R1]6+ , red curve= [pyrene-
R2]6+ , green curve= [pyrene-R3]6+) as solutions (107m) in H2O/
DMSO (99.5:0.5, v/v) at 21 8C. Excitation at 350 nm. Inset: titration at
21 8C of [2] ACHTUNGTRENNUNG[CF3SO3]6 (0.1–6.0 equiv) versus a solution containing pyrene-
R under the same conditions.
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the summation of two electronic effects. First, as the pyrenyl
part is trapped in the cavity of the metalla-prism, a fraction
of the excitation energy normally absorbed by this guest
molecule is intercepted by the host molecule, that is, static
quenching. Secondly, quenching can also result from energy
transfer from the pyrenyl group to the metalla-prism.
Indeed, due to good spectral overlap of the absorbance of
metalla-prisms [1–3]6+ with the pyrenyl emission, energy
transfer can spontaneously take place, thus leading to a de-
crease in the emission energy of the pyrenyl moiety and ulti-
mately to fluorescence quenching.[27] On the other hand, be-
cause the triazin-2-yl group dangles out of the cavity of the
metalla-prism, these two effects are not observed and thus
the fluorescence intensity of this triazin-2-yl unit is con-
served. This partial quenching of the fluorescence of
pyrene-R in metalla-prisms [1–3]6+ is illustrated by the
emission spectra from the fluorescence titrations (see
Figure 7). Upon gradual addition of [1–3]ACHTUNGTRENNUNG[CF3SO3]6 (0.1–
6.0 equiv) to a H2O/DMSO (99.5:0.5, v/v) solution of
pyrene-R (107m), the emission spectra (excitation: 350 nm,
21 8C) show a strong quenching of the band associated with
the pyrenyl part, whereas the band associated with the tri-
ACHTUNGTRENNUNGazin-2-yl group is less affected by the addition of [1–3]6+ .
Because we were unable to obtain an X-ray crystal struc-
ture of any of the host–guest systems, molecular modelling
in the gas phase using the HyperChem software was used to
construct each metalla-prism and the outputs of the simula-
tions are presented in Figure 8.[28] These molecular dynamics
simulations allow the portal sizes of these cages to be esti-
mated in the gas phase. The largest portal, estimated to be
approximately 7.410.2 2, is found in [pyrene-R1]6+ ,
which exhibits the highest fluorescence, that is, the most
facile loss of the pyrene-R guest. Compound [pyrene-
R3]6+ , which contains the smallest portal (7.47.8 2), ex-
hibits the least fluorescence, which corresponds to a more
stable host–guest system. These observations are in line with
the free energies determined for these systems (see Table 1)
and the release of the guest correlates very well with the
corresponding portal sizes.
To assess the ability of the metalla-cages to improve the
efficacy of biologically active compounds, the cytotoxicities
of the cages, alone or with the pyrene-R or Pd ACHTUNGTRENNUNG(acac)2 guests,
were established on the A2780 ovarian cancer cell line
(Table 2). The cytotoxicities of the two ’free’ guest mole-
cules, pyrene-R and Pd ACHTUNGTRENNUNG(acac)2, could not be determined due
to their poor solubility. The cytotoxicities of pyrene-R and
Pd ACHTUNGTRENNUNG(acac)2 inside the cage systems is systematically higher
than that of the corresponding cages. Moreover, the [Pd-
ACHTUNGTRENNUNG(acac)21–3]6+ systems are more cytotoxic than the corre-
sponding [pyrene-R1–3]6+ systems, behaviour that is con-
sistent with other supramolecular drug systems.[18] The IC50
values indicate that the cage–guest complex acts as a drug-
delivery system with the cage ensuring entry of the guest
into the cancer cells, with the pyrene-R or Pd ACHTUNGTRENNUNG(acac)2 acting
on cell metabolism following intracellular release.
Because the efficacy of a drug is related to its ability to
cross the cell membrane, size and lipophilicity are crucial
properties that profoundly influence drug molecules.[29,30] To
gain further insight into the modes of uptake of these host–
guest systems, we measured the intracellular ruthenium con-
tent, which reflects the uptake of the metalla-cage and the
intrinsic fluorescence of the pyrene. The uptake of rutheni-
um into the cells was determined for the [pyrene-R1–3]6+
systems by inductively coupled plasma mass spectroscopy
(ICP-MS), which reveals that all the compounds enter the
cells to essentially the same extent (see Figure 9A) and indi-
cates a similar uptake mechanism for the three supramolec-
ular complexes. As previously reported, the fluorescence of
pyrene-R is partially quenched inside the ruthenium cage[18]
and consequently fluorescence can be used to evaluate the
release of free pyrene-R inside the A2780 cells. Interesting-
ly, flow cytometric analysis of
cells incubated with [pyrene-
R1–3]6+ (see Figure 9A) re-
veals that the ratio between
cell fluorescence and the intra-
cellular ruthenium concentra-
tion varies as a function of the
metalla-cage used to entrap
the pyrene-R fluorophore. Es-
sentially, there is a clear corre-
lation between the portal size
of the host and the release of
pyrene-R.
Figure 8. HyperChem simulations of the metalla-cages [pyrene-R1–3]6+ .
Table 2. Cytotoxicity of compounds towards A2780 cells (72 h incuba-
tion).
Compound IC50 [mm] SD [mm]
pyrene-R ND ND
Pd ACHTUNGTRENNUNG(acac)2 ND ND
[1] ACHTUNGTRENNUNG[CF3SO3]6 3.2 1.1
[2] ACHTUNGTRENNUNG[CF3SO3]6 13.1 1.1
[3] ACHTUNGTRENNUNG[CF3SO3]6 4.1 0.1
[pyrene-R1] ACHTUNGTRENNUNG[CF3SO3]6 1.9 0.1
[pyrene-R2] ACHTUNGTRENNUNG[CF3SO3]6 2.3 0.6
[pyrene-R3] ACHTUNGTRENNUNG[CF3SO3]6 1.1 0.2
[Pd ACHTUNGTRENNUNG(acac)21] ACHTUNGTRENNUNG[CF3SO3]6 <0.3 ND
[Pd ACHTUNGTRENNUNG(acac)22] ACHTUNGTRENNUNG[CF3SO3]6 0.9 0.3
[Pd ACHTUNGTRENNUNG(acac)23] ACHTUNGTRENNUNG[CF3SO3]6 <0.3 ND
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The mode of passage across the cell membrane of these
molecules is also relevant. Due to their size, the molecules
are putatively taken up by the cells by endocytosis, com-
monly assumed to be active, rather than by a cell-specific
uptake mechanism on which an increasing amount of cancer
research is focused.[29] The uptake mechanism of [pyrene-
R1]6+ was also studied with uptake found to be both tem-
perature- and wortmannin-sensitive (see Figure 9B). Wort-
mannin blocks specific endocytic mechanisms and has been
widely used to study intracellular transport mechanisms.[30,31]
Combined, these studies indicate that the uptake of [pyrene-
R1]6+ involves endocytosis/macropinocytosis rather than
passive diffusion across the cell membrane.
Following release of pyrene-R from the host, confocal mi-
croscopy was used to show that the pyrene-R stains vesicle-
like cytoplasmic organelles and accumulates in the intracel-
lular vesicle part of the cell endocytotic system.[32] A previ-
ous microscopy study showed that pyrene-R accumulates in
cytoplasmic organelles.[18] In an attempt to better identify
these organelles, their fluorescence pattern was com-
pared with that of two known
fluorescent reporters, the lyso-
somal dye Lysotracker Red and
the fluid-phase endocytosis
marker FITC-dextran (see
Figure 10).[33] After 24 h of in-
cubation, the free pyrene-R
does not enter lysosomal com-
partments and does not accu-
mulate in the endocytic com-
partments that are enriched in
FITC-dextran, which suggests
that pyrene-R accumulates in
endocytic rather than lytic com-
partments. Hence, it would
appear that the [1–3]6+ drug
carriers promote the accumula-
tion of pyrene-R in a compart-
ment in which protection from
lysosomal and cytoplasmic detoxification takes place.
Conclusion
We have described herein the synthesis, characterisation,
host–guest properties and in vitro characterisation of a mod-
ular and adjustable supramolecular drug-delivery system
based on hexaruthenium metalla-cages. Moreover, we have
shown that the host molecules, which have similar sized cav-
ities but different portal sizes, deliver their guests inside the
cell with different efficiencies. Not only have cytotoxicity
studies shown a synergistic effect between the metalla-cages
and two non-related hydrophobic guest molecules, pyrene-R
and Pd ACHTUNGTRENNUNG(acac)2, but these studies also highlight other relevant
features of this promising drug-delivery strategy. The portal
size of the cage influences the ability to release the host.
Nevertheless, all cages deliver the host to similar intracellu-
lar organelles. Through the use of specific inhibitors and flu-
orescent reporters, we have shown that endocytosis is proba-
bly involved in the uptake and leads to the accumulation of
the guest molecule in intracellular organelles.
Experimental Section
2,4,6-Tris(pyridine-4-yl)-1,3,5-triazine (tpt)[34] and [Ru2(p-iPrC6H4Me)2-
ACHTUNGTRENNUNG(OO\OO)Cl2] (OO\OO=donq,[19] doaq[35] and dotq[24f]) were prepared
according to published methods. 1-(4,6-Dichloro-1,3,5-triazin-2-yl)pyrene,
Pd ACHTUNGTRENNUNG(acac)2 and all other reagents were commercially available (Sigma–Al-
drich) and used as received. All NMR measurements (1H, 13C{1H}, 2D
and DOSY) were recorded on a Bruker AMX 400 spectrometer using
the residual protonated solvent as internal standard. Infrared spectra
were recorded as KBr pellets on a Perkin–Elmer FTIR 1720-X spectrom-
eter. UV/Vis absorption spectra were recorded on an Uvikon 930 spec-
trophotometer using precision cells made of quartz (1 cm). Fluorescence
spectra were recorded on a Luminescence Perkin–Elmer LS50B spec-
trometer using precision cells made of quartz (1 cm). Elemental analyses
were performed by the Mikroelementarisches Laboratorium, ETH
Figure 10. Confocal microscopy of A2780 cells incubated with [pyrene-
R2] ACHTUNGTRENNUNG[CF3SO3]6 at 2 mm for 24 h. Pyrene-R fluorescence (blue), FITC-
dextran (green) and Lysotracker Red (red) were imaged. The fluores-
cence image is shown on the left and the transmitted-light picture on the
right (scale bar=10 mm).
Figure 9. A) Fluorescence recorded by flow cytometry of [pyrene-R1–3]6+ indicating pyrene-R release from
the host (blue). Ruthenium uptake determined by ICP-MS is also shown (red). Cells were incubated with [1]-
ACHTUNGTRENNUNG[CF3SO3]6 and [pyrene-R1–3] ACHTUNGTRENNUNG[CF3SO3]6 at 2 mm for 24 h. B) Quantification of the intracellular fluorescence
by flow cytometry of A2780 incubated with [pyrene-R1]6+ after 1 h pre-incubation in the culture medium
(untreated; left), pre-incubated at 4 8C (centre) and pre-incubated with wortmannin (right). The results repre-
sent the percentage of fluorescence intensity relative to the untreated sample.
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Zrich, or the Laboratory of Pharmaceutical Chemistry, University of
Geneva (Switzerland).
For all DOSY experiments, the temperature was regulated at 298 K, the
airflow was increased to 670 Lmin1 and the NMR tube was spun. The
diffusion NMR experiments were performed by using a standard pulsed-
gradient stimulated echo (LED-PFGSTE) sequence using a bipolar gra-
dient.[24] DOSY spectra were generated by using the TopSpin 2.0 software
package.[36] Experimental parameters were D=50.0 ms (diffusion delay),
t=1.0 ms (gradient recovery delay) and Te=5.0 ms (eddy current recov-
ery delay). For each data set, 4096 complex points were collected and the
gradient dimension was sampled in 16 experiments in which the gradient
strength was gradually increased from 1.0 to 50.8 Gcm1. The gradient
duration d/2 was adjusted to observe a near complete signal loss at
50.8 Gcm1. Typically, a d/2 delay of 1.2–2.0 ms was chosen. A 1.0 s recy-
cle delay was used between scans for the data shown. For each data set,
the spectral axis was processed with an exponential function (3–5 Hz
line-broadening) and a Fourier transform was applied to obtain 4096 real
points. The DOSY reconstruction was realised with 256 points in the dif-
fusion dimension. The number of scans ranged from 8 to 64 and was
adapted to each sample. The experimental time ranged from 4 to 30 min.
Syntheses of [guest1–3]ACHTUNGTRENNUNG[CF3SO3]6 : A mixture of Ag ACHTUNGTRENNUNG(CF3SO3) (72 mg,
0.28 mmol), [Ru2 ACHTUNGTRENNUNG(p-cymene)2 ACHTUNGTRENNUNG(OO\OO)Cl2] (OO\OO=1: donq: 102 mg;
2 : doaq: 109 mg; 3 : dotq: 116 mg; 0.14 mmol), tpt (29 mg, 0.09 mmol)
and guest molecule Pd ACHTUNGTRENNUNG(acac)2 (14 mg, 0.05 mmol) or 1-(4,6-dichloro-1,3,5-
triazin-2-yl)pyrene (17 mg, 0.05 mmol)in CH3OH (30 mL) was stirred at
60 8C for 12 h. The solvent was then filtered and the residue was dis-
solved in CH2Cl2 (3 mL) and diethyl ether was slowly added to precipi-
tate the solid, which was filtered and dried under vacuum.
[Pd ACHTUNGTRENNUNG(acac)21] ACHTUNGTRENNUNG[CF3SO3]6 : Yield: 143 mg (75%); 1H NMR (400MHz,
CD3CN): d=8.60 (d,
3J ACHTUNGTRENNUNG(H,H)=6.5 Hz, 12H; Ha), 8.34 (d,
3J ACHTUNGTRENNUNG(H,H)=
6.5 Hz, 12H; Hb), 7.29 (s, 12H; Hq), 5.70 (d,
3J ACHTUNGTRENNUNG(H,H)=5.9 Hz, 12H;
Hcym), 5.52 (d, 12H; Hcym), 3.45 (m, 2H; CHacac), 2.80 (sept.,
3J ACHTUNGTRENNUNG(H,H)=
6.9 Hz, 6H; CH ACHTUNGTRENNUNG(CH3)2), 2.10 (s, 18H; CH3), 1.30 (d, 36H; CH ACHTUNGTRENNUNG(CH3)2),
0.02 ppm (m, 12H; CH3acac);
13C{1H} NMR (100MHz, CD3CN): d=172.0
(CO), 170.1 (Ctpt), 156.2 (CHa), 147.0 (Ctpt), 135.4 (CHq), 123.9 (CHb),
111.5 (Cq), 103.8 (Ccym), 102.0 (CHacac), 100.5 (Ccym), 84.7 (CHcym), 84.2
(CHcym), 31.4 (CH ACHTUNGTRENNUNG(CH3)2), 23.1 (CH ACHTUNGTRENNUNG(CH3)2), 22.1 (CH ACHTUNGTRENNUNG(CH3)2), 17.4
(CH3), 15.7 ppm (CH3acac); IR (KBr): n˜=3060 (w, CHaryl), 1536 (s, C=O),
1260 cm1 (s, CF3); UV/Vis (1.010
5m, CH2Cl2): lmax (e)=308 (3.99
105), 374 (0.75105), 526 (0.17105), 568 (0.24105), 612 nm (0.29
105m1 cm1); elemental analysis calcd (%) for C142H134F18N12O34PdRu6S6:
C 44.88, H 3.55, N 4.42; found: C 44.21, H 3.53, N 4.33.
[Pd ACHTUNGTRENNUNG(acac)22] ACHTUNGTRENNUNG[CF3SO3]6 : Yield: 147 mg (74%); 1H NMR (400MHz,
CD3CN): d=8.81 (m, 6H; Hq), 8.64 (m, 12H; Ha), 8.15 (m, 6H; Hq), 8.05
(m, 12H; Hb), 7.42 (m, 6H; Hq), 5.81 (d,
3J ACHTUNGTRENNUNG(H,H)=5.6 Hz, 12H; Hcym),
5.63 (d, 12H; Hcym), 3.49 (m, 2H; CHacac), 2.81 (sept.,
3J ACHTUNGTRENNUNG(H,H)=6.8 Hz,
6H; CH ACHTUNGTRENNUNG(CH3)2), 2.11 (s, 18H; CH3), 1.30 (d, 36H; CHACHTUNGTRENNUNG(CH3)2), 0.02 ppm
(m, 12H; CH3acac);
13C{1H} NMR (100MHz, CD3CN): d=171.5 (CO),
170.5 (CO), 169.9 (Ctpt), 157.9 (CHa), 144.8 (Ctpt), 139.8 (CHq), 134.7
(CHq), 129.6 (CHq), 124.9 (CHb), 110.7 (Cq), 103.8 (Ccym), 102.0 (CHacac),
101.2 (Ccym), 89.7 (CHcym), 88.6 (CHcym), 85.2 (CHcym), 84.7 (CHcym), 31.4
(CH ACHTUNGTRENNUNG(CH3)2), 22.5 (CH ACHTUNGTRENNUNG(CH3)2), 22.1 (CH ACHTUNGTRENNUNG(CH3)2), 17.6 (CH3), 15.5 ppm
(CH3acac); IR (KBr): n˜=3060 (w, CHaryl), 1536 (s, C=O), 1260 cm
1 (s,
CF3); UV/Vis (1.010
5m, CH2Cl2): lmax (e)=308 (3.9510
5), 371 (0.66
105), 447 (0.50105), 648 nm (0.22105m1 cm1); elemental analysis
calcd (%) for C154H140F18N12O34PdRu6S6: C 46.83, H 3.57, N 4.26; found:
C 46.31, H 3.54, N 4.15.
[Pd ACHTUNGTRENNUNG(acac)23] ACHTUNGTRENNUNG[CF3SO3]6 : Yield: 157 mg (77%); 1H NMR (400MHz,
CD3CN): d=8.80 (dd,
3J ACHTUNGTRENNUNG(H,H)=6.3 Hz, 4J ACHTUNGTRENNUNG(H,H)=3.1 Hz, 12H; Hq), 8.51
(d, 3J ACHTUNGTRENNUNG(H,H)=6.5 Hz, 12H; Ha), 8.02 (m, 24H; Hq+Hb), 5.90 (d,
3J-
ACHTUNGTRENNUNG(H,H)=6.1 Hz, 12H; Hcym), 5.60 (d, 12H; Hcym), 3.51 (m, 2H; CHacac),
2.79 (sept., 3J ACHTUNGTRENNUNG(H,H)=6.4 Hz, 6H; CH ACHTUNGTRENNUNG(CH3)2), 2.10 (s, 18H; CH3), 1.30
(d, 36H; CH ACHTUNGTRENNUNG(CH3)2), 0.02 ppm (m, 12H; CH3acac);
13C{1H} NMR
(100 MHz, CD3CN): d=170.0 (CO), 165.7 (Ctpt), 152.2 (CHa), 141.3
(Ctpt), 133.1 (Cq), 132.6 (CHq), 127.0 (CHq), 123.2 (CHb), 106.5 (Cq), 103.4
(Ccym), 102.2 (CHacac), 101.1 (Ccym), 85.2 (CHcym), 85.1 (CHcym), 84.8
(CHcym), 84.6 (CHcym), 31.2 (CH ACHTUNGTRENNUNG(CH3)2), 22.1 (CH ACHTUNGTRENNUNG(CH3)2), 22.0 (CH-
ACHTUNGTRENNUNG(CH3)2), 17.9 (CH3), 15.8 ppm (CH3acac); IR (KBr): n˜=3060 (w, CHaryl),
1536 (s, C=O), 1260 cm1 (s, CF3); UV/Vis (1.010
5m, CH2Cl2): lmax
(e)=308 (3.90105), 380 (0.56105), 607 (0.20105), 655 nm (0.22
105m1 cm1); elemental analysis calcd (%) for C166H146F18N12O34PdRu6S6:
C 48.63, H 3.59, N 4.10; found: C 47.92, H 3.57, N 4.02.
[Pyrene-R1] ACHTUNGTRENNUNG[CF3SO3]6 : Yield: 149 mg (77%); 1H NMR (400 MHz,
CD3CN): d=8.40 (d,
3J ACHTUNGTRENNUNG(H,H)=6.6 Hz, 12H; Ha), 7.78 (m, 12H; Hb), 7.47
(s, 12H; Hq), 7.25 (m, 1H; Hpyr), 7.08 (m, 1H; Hpyr), 6.12 (m, 1H; Hpyr),
5.82 (m, 1H; Hpyr), 8.75 (m, 1H; Hpyr), 5.69 (d,
3J ACHTUNGTRENNUNG(H,H)=5.7 Hz, 12H;
Hcym), 5.44 (d, 12H; Hcym), 5.22 (m, 1H; Hpyr), 4.92 (m, 1H; Hpyr), 4.81
(m, 1H; Hpyr), 4.75 (m, 1H; Hpyr), 2.80 (sept.,
3J ACHTUNGTRENNUNG(H,H)=6.7 Hz, 6H; CH-
ACHTUNGTRENNUNG(CH3)2), 2.07 (s, 18H; CH3), 1.32 ppm (d, 36H; CH ACHTUNGTRENNUNG(CH3)2);
13C{1H}
NMR (100MHz, CD3CN): d=171.2 (CO), 170.5 (Ctpt), 155.1 (CHa),
144.3 (Ctpt), 139.9 (CHq), 130.8 (Cpyr), 128.6 (CHpyr), 127.8 (CHpyr), 126.6
(Cpyr), 126.2 (CHb), 115.5 (Cq), 104.8 (Ccym), 100.4 (Ccym), 85.1 (CHcym),
84.6 (CHcym), 31.4 (CH ACHTUNGTRENNUNG(CH3)2), 23.0 (CH ACHTUNGTRENNUNG(CH3)2), 22.1 (CH ACHTUNGTRENNUNG(CH3)2),
17.3 ppm (CH3); IR (KBr): n˜=3060 (w, CHaryl), 1536 (s, C=O), 1500 (m,
C=C), 1260 cm1 (s, CF3); UV/Vis (1.010
5m, CH2Cl2): lmax (e)=308
(3.88105), 377 (0.47 105), 563 (0.24105), 613 nm (0.17105m1 cm1);
elemental analysis calcd (%) for C151H129Cl2F18N15O30Ru6S6: C 47.16, H
3.38, N 5.46; found: C 47.08, H 3.46, N 5.42.
[Pyrene-R2] ACHTUNGTRENNUNG[CF3SO3]6 : Yield: 146 mg (73%); 1H NMR (400 MHz,
CD3CN): d=8.78 (m, 6H; Hq), 8.60 (m, 12H; Ha), 8.09 (m, 6H; Hq), 8.01
(m, 12H; Hb), 7.96 (m, 1H; Hpyr), 7.71 (m, 1H; Hpyr), 7.40 (m, 6H; Hq),
7.21 (m, 1H; Hpyr), 7.01 (m, 1H; Hpyr), 5.98 (m, 1H; Hpyr), 5.81 (d,
3J-
ACHTUNGTRENNUNG(H,H)=5.8 Hz, 12H; Hcym), 5.62 (d, 12H; Hcym), 5.52 (m, 1H; Hpyr), 5.09
(m, 1H; Hpyr), 4.96 (m, 1H; Hpyr), 4.75 (m, 1H; Hpyr), 2.80 (sept.,
3J-
ACHTUNGTRENNUNG(H,H)=6.7 Hz, 6H; CH ACHTUNGTRENNUNG(CH3)2), 2.10 (s, 18H; CH3), 1.29 ppm (d, 36H;
CH ACHTUNGTRENNUNG(CH3)2);
13C{1H} NMR (100MHz, CD3CN): d=170.5 (CO), 170.2
(CO), 169.8 (Ctpt), 156.7 (CHa), 142.4 (Ctpt), 141.0 (CHq), 135.6 (CHq),
130.2 (CHq), 129.7 (Cpyr), 128.2 (CHpyr), 126.8 (CHpyr), 126.2 (Cpyr), 125.9
(CHb), 109.1 (Cq), 104.9 (Ccym), 101.1 (Ccym), 88.6 (CHcym), 87.8 (CHcym),
86.1 (CHcym), 85.9 (CHcym), 32.2 (CH ACHTUNGTRENNUNG(CH3)2), 22.9 (CH ACHTUNGTRENNUNG(CH3)2), 22.7 (CH-
ACHTUNGTRENNUNG(CH3)2), 17.0 ppm (CH3); IR (KBr): n˜=3060 (w, CHaryl), 1536 (s, C=O),
1500 (m, C=C), 1260 cm1 (s, CF3); UV/Vis (1.010
5m, CH2Cl2): lmax
(e)=308 (3.79105), 442 (0.36105), 659 nm (0.18105m1 cm1); ele-
mental analysis calcd (%) for C163H135Cl2F18N15O30Ru6S6: C 49.00, H 3.41,
N 5.26; found: C 48.91, H 3.48, N 5.22.
[Pyrene-R3] ACHTUNGTRENNUNG[CF3SO3]6 : Yield: 155 mg (75%); 1H NMR (400 MHz,
CD3CN): d=8.90 (m, 12H; Ha), 8.84 (m, 12H; Hb), 8.11 (m, 12H; Hq),
7.90 (m, 1H; Hpyr), 7.75 (m, 1H; Hpyr), 7.22 (m, 12H; Hq), 7.18 (m, 1H;
Hpyr), 7.09 (m, 1H; Hpyr), 6.31 (m, 1H; Hpyr), 5.88 (d,
3J ACHTUNGTRENNUNG(H,H)=6.2 Hz,
12H; Hcym), 5.61 (d, 12H; Hcym), 5.35 (m, 1H; Hpyr), 5.18 (m, 1H; Hpyr),
4.88 (m, 1H; Hpyr), 4.71 (m, 1H; Hpyr), 2.80 (sept.,
3J ACHTUNGTRENNUNG(H,H)=6.6 Hz, 6H;
CH ACHTUNGTRENNUNG(CH3)2), 2.09 (s, 18H; CH3), 1.32 ppm (d, 36H; CHACHTUNGTRENNUNG(CH3)2);
13C{1H}
NMR (100 MHz, CD3CN): d=171.1 (CO), 166.9 (Ctpt), 151.3 (CHa),
140.2 (Ctpt), 133.1 (Cq), 132.8 (CHq), 131.2 (Cpyr), 128.9 (CHpyr), 128.2
(CHpyr), 127.4 (Cpyr), 126.9 (CHq), 124.3 (CHb), 105.5 (Cq), 104.8 (Ccym),
100.9 (Ccym), 85.4 (CHcym), 85.3 (CHcym), 85.1 (CHcym), 84.9 (CHcym), 31.0
(CH ACHTUNGTRENNUNG(CH3)2), 22.2 (CH ACHTUNGTRENNUNG(CH3)2), 20.9 (CHACHTUNGTRENNUNG(CH3)2), 18.1 ppm (CH3); IR
(KBr): n˜=3060 (w, CHaryl), 1536 (s, C=O), 1500 (m, C=C), 1260 cm
1 (s,
CF3); UV/Vis (1.010
5m, CH2Cl2): lmax (e)=308 (3.6010
5), 390 (0.23
105), 607 (0.14105), 658 nm (0.13105m1 cm1); elemental analysis
calcd (%) for C175H141Cl2F18N15O30Ru6S6: C 50.70, H 3.43, N 5.07; found:
C 49.97, H 3.41, N 4.97.
Culture and inhibition of cell growth : Human A2780 ovarian carcinoma
cells were obtained from the European Centre of Cell Cultures
(ECACC, Salisbury, UK) and maintained in culture as described by the
provider. The cells were routinely grown in RPMI 1640 medium contain-
ing 10% foetal calf serum (FCS) and antibiotics at 37 8C and under 5%
CO2. To evaluate growth inhibition, the cells were seeded in 96-well
plates (25000 cells per well) and grown for 24 h in complete medium.
Compounds were added to the cell culture to the required concentration
and incubated for 72 h. Solutions of the compounds were applied by di-
luting a freshly prepared stock solution of the corresponding compound
in DMSO, with the final concentration of 0.05% in the medium. The 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test
was performed in the last 2 h without changing the culture medium. Fol-
lowing drug exposure, MTT (from Sigma) was added to the cells at a
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final concentration of 0.2 mgmL1 and incubated for 2 h, then the culture
medium was aspirated and the violet formazan precipitate dissolved in
DMSO. The optical density was quantified at 540 nm by using a multiwell
plate reader (iEMS Reader MF, Labsystems, USA), and the percentage
of surviving cells was calculated from the ratio of absorbance of treated
to untreated cells. The IC50 values for the inhibition of cell growth were
determined by fitting the plot of the percentage of surviving cells against
the drug concentration using a sigmoidal function (Origin v7.5).[37]
Microscopy experiments : Cells were grown for 24 h on chambered cover-
glass (Lab-Tek, NUNC) slides in complete medium at a density of 1
104 cells per well and later exposed to the appropriate compound at 37 8C
in the dark. Cells were stained with Lysotracker Red DND-99 (Invitro-
gen, Molecular Probes) and 10 kDa FITC-dextran (Invitrogen, Molecular
Probes) for 30 min at 37 8C. Excess complex was washed away with PBS,
fixed with 4% formaldehyde in PBS for 30 min in the dark and rinsed
twice with PBS before observation. Cells were mounted in PBS before
being observed by confocal microscopy using a Zeiss LSM 700 inverted
microscope equipped with a 40X oil immersion objective. Filters used for
the excitation and detection of pyrene-R were 405 and 492 nm, respec-
tively, 488 and 559 nm for the detection of FITC-dextran, and 555 and
587 nm for the detection of Lysotracker Red DND-99. The intensities of
the fluorescence signals were evaluated by using the Zen software.[38]
Flow cytometry : Cells were detached from the culture with EDTA
(0.48 mm in PBS) and incubated at 1106 cells/mL with [pyrene-R1–3]-
ACHTUNGTRENNUNG[CF3SO3]6 salts (added from a concentrated DMSO stock) under the con-
ditions described above and then placed on ice. The fluorescence of
~20000 cells was measured by using a BD LSR II analyser, exciting with
a 355 nm laser for pyrene-R. Emission was observed at 45040 nm. The
fluorescence data were analysed by using the FlowJo 8 software.[39]
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